



---

GLOBAL MALARIA PROGRAMME, JUNE 2009

---

# Deployment of artemether- lumefantrine with rapid diagnostic tests at community level, Raya Valley, Tigray, Ethiopia



**World Health  
Organization**



GLOBAL MALARIA PROGRAMME

# **Deployment at community level of artemether-lumefantrine and rapid diagnostic tests**

*Raya Valley, Tigray, Ethiopia*

---

PROJECT REPORT, APRIL 2005–JUNE 2007

---

MALARIA AND OTHER VECTOR-BORNE DISEASES CONTROL DEPARTMENT,  
TIGRAY HEALTH BUREAU, ETHIOPIA



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

Deployment of artemether-lumefantrine with rapid diagnostic tests at community level, Raya Valley, Tigray, Ethiopia.

1.Malaria - drug therapy. 2.Antimalarials - economics. 3.Drug therapy, Combination. 4.Artemisinin - supply and distribution. 4.Artemisinin - therapeutic use. 5.Ethanolamines - therapeutic use. 6.Flourenes - therapeutic use. 7.Ethiopia. I.World Health Organization. Global Malaria Programme

ISBN 978 92 4 159837 8

(NLM classification: QV 256)

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr Andrea Bosman, Global Malaria Programme  
World Health Organization  
20, avenue Appia – CH-1211 Geneva 27  
infogmp@who.int  
www.who.int/malaria

© World Health Organization, 2009.

All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Photograph of community health worker on the front cover: *Courtesy of Angela Bianchi, Novartis Italy*

# Contents

<i>Acknowledgements</i>	v
<i>Preface</i>	vii
<i>Executive summary</i>	viii
<b>1. Introduction</b>	1
<b>2. Study area</b>	4
2.1 Geography and demography	4
2.2 Potential effect on vector control of malaria epidemic during the study	5
2.2.1 Meteorological conditions	5
2.2.2 Concurrent vector control	8
2.3 Health service infrastructure in Tigray	10
<b>3. Methods</b>	11
3.1 Study design	11
3.2 Data collection	12
3.2.1 Institution-based morbidity, slide positivity, malaria admissions, case fatality and proportionate mortality rates	13
3.2.2 Institution-based survey of adherence and study of performance of rapid diagnostic tests in the intervention district	13
3.2.3 Community-based malaria morbidity reports in the intervention district	14
3.2.4 Community-based surveys	14
3.2.5 Pharmacovigilance	18
3.2.6 Capacity-building and database management	19
<b>4. Results and discussion</b>	22
4.1 Profile of community health workers and training outcomes	22
4.1.1 Characteristics of community health workers	22
4.1.2 Training outcomes	22
4.2 Community treatment services	23
4.2.1 Numbers of cases treated	23
4.2.2 Pattern of service by age and gender	23
4.2.3 Prescription for artemether-lumefantrine	27
4.3 Serial surveys of seasonal prevalence of malaria and of knowledge, attitude and practices	28
4.3.1 Seasonal prevalence of malaria	28
4.3.2 Knowledge, attitude and practices	30
4.4 Performance of rapid diagnostic tests	32
4.4.1 Health institution level	32
4.4.2 Community health worker level	33

4.5	Adherence of patients to the 6-dose artemether-lumefantrine regimen	35
4.6	Pharmacovigilance	39
4.7	Health impact of use of rapid diagnostic tests and artemether-lumefantrine	40
4.7.1	Morbidity trends at clinics and health posts	40
4.7.2	Morbidity trends at health centres and the hospital	41
4.8	Mortality surveys	44
4.9	Challenges to assessing impact	49
4.10	Satisfaction of beneficiaries of the project	50
4.11	Cost of diagnosis clinically and with the rapid diagnostic test at community level	52
<b>5.</b>	<b>Lessons learnt</b>	<b>53</b>
5.1	Study design	53
5.2	Project personnel	53
5.3	Database management	53
5.4	Logistics	53
5.5	Project management	54
5.6	Capacity-building	54
5.7	Effect of low incidence of malaria in Phase II of the project	54
<b>6.</b>	<b>Project budget</b>	<b>55</b>
6.1	Project budget input and expenditure	55
6.2	Financing and supplies	56
6.3	Operational costs	57
<b>7.</b>	<b>Monitoring and evaluation</b>	<b>58</b>
<b>8.</b>	<b>Conclusions</b>	<b>60</b>
<b>9.</b>	<b>Recommendations</b>	<b>63</b>
<b>Appendix A.</b>	<b>Maps</b>	<b>66</b>
<b>Appendix B.</b>	<b>Summary tables</b>	<b>68</b>
<b>Appendix C.</b>	<b>Project timetable</b>	<b>73</b>

## Acknowledgements

*The Tigray Health Bureau, the World Health Organization (WHO) through its Global Malaria Programme, the Italian Ministry of Labour, Health and Social Policies – Health Sector, Novartis Farma SPA (Italy), the Department of Preventive Medicine in Migration, Tourism and Tropical Dermatology of the San Gallicano Hospital (IRCCS) and the Italian Dermatological Centre of Mekelle are grateful to all the institutions and individuals that contributed their time, energy and funding to make this project successful.*

*Special thanks are due to Dr Tedros Adhanom, Minister of Health of Ethiopia, Dr Gebre Ab Barnabas, Head of the Tigray Health Bureau, Mr Hailemariam Lemma, Mr Alem Desta and Mr Asefaw Getachew of the Malaria Control Department of the Tigray Health Bureau, and Dr Andrea Bosman and Dr Wilson Were of the WHO Global Malaria Programme, for their dedicated efforts throughout the project. Monitoring and follow-up of the project would have been impossible without the involvement of Dr Gianfranco Costanzo of the Italian Ministry of Labour, Health and Social Policies – Health Sector Department of Innovation, Ms Angela Bianchi (Novartis Farma SPA, Italy), Dr Anne-Claire Marrast (Novartis Pharma AG, Basel) and Professor Aldo Morrone and Dr Luigi Toma (Department of Preventive Medicine in Migration, Tourism and Tropical Dermatology of the San Gallicano Hospital in Rome), Dr Nathan Mulure (Novartis Pharma, Nairobi, Kenya), Mr Roberto Ferrara (Novartis Farma SPA, Italy), Mr Ambachew Medhin (WHO Ethiopia) and Dr Giacomo Stefanoni (intern, Department of Preventive Medicine in Migration, Tourism and Tropical Dermatology, San Gallicano, Rome). These individuals also provided administrative and technical guidance, comments to strengthen the project and continuous monitoring of activities through regular teleconferences.*

*Grateful thanks are also due to Mr Hailemariam Lemma, Mr Alem Desta, Mr Goitom Mehari and Mr Abrha Kahsay for their personal commitment in preparing operational manuals for the different project tasks, training participants and regularly tracking project activities, including data management, and to Mr Berhane Hailesilassie for designing, conducting and summarizing the focus group discussions. Professor Peter Byass and Dr Edward Fottrell (Umeå University, Sweden) were responsible for the design, implementation and analysis of the*

*mortality survey; and Ms Appia Augustina Appiah-Danquah (University of Ghana Medical School, Accra) contributed to the mid-term evaluation of the pharmacovigilance activities. The contributions of the Italian Ministry of Labour, Health and Social Policies – Health Sector and of Novartis Farma SPA (Italy), which provided financial support to this project are gratefully acknowledged.*

*Above all, however, the key elements in the success of this project were the community health workers, who generously volunteered their and their families' valuable time, resources and efforts to best serve people affected by malaria in remote rural areas. Last but not least, this project would not have been possible without the full involvement and continuous support of the communities, the health authorities and the health workers in both districts throughout the project.*

预览已结束，完整报告链接和二维码

<https://www.yunbaogao.cn/report/index/report?rep>